Prognostic factors in chronic lymphocytic leukemia;Czynniki prognostyczne w przewlekłej białaczce limfatycznej

Acta Haematologica Polonica

Volumn 34, Issue 4, 2003, Pages 395-405

  Robak, Tadeusz ^a  

^a Klinika Hematologii   (Poland)

Author keywords

CD38; Chronic lymphocytic leukemia; Clinical staging; Cytogenesis; IgVH gen mutation; Prognosis; Serum markers; ZAP 70

Indexed keywords

BETA 2 MICROGLOBULIN; CD23 ANTIGEN; CD38 ANTIGEN; HERMES ANTIGEN; LACTATE DEHYDROGENASE; PROTEIN KINASE ZAP 70; THYMIDINE KINASE; TUMOR MARKER;

ADVANCED CANCER; AUTOIMMUNE DISEASE; B CELL LEUKEMIA; BONE MARROW; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 11Q; CHROMOSOME 17P; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CYTOPENIA; GENE EXPRESSION; HUMAN; HYPERSPLENISM; IMMUNOGLOBULIN VARIABLE REGION; LIFESPAN; LYMPHOCYTE COUNT; LYMPHOID CELL; PROGNOSIS; REVIEW; SOMATIC MUTATION;

EID: 1042265264     PISSN: 00015814     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Calgaris-Cappio F, Hamblin TJ. B-cell chronic lymphocytic leukemia a bird of a different feather. J Clin Oncol. 1999; 17: 399-408.
2. Montserrat E, Rozman C. Chronic lymphocytic leukemia: present status. Ann Oncol. 1996; 6: 219-235.
3. Dighiero G. Is chronic lymphocytic leukemia one disease. Haematologica 2002; 87: 1233-1235.
4. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219-234.
5. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J. et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198-206.
6. Montserrat E. Classical and new prognostic factors in chronic lymphocytic leukemia: where to now?. Hematology J. 2002; 3: 7-9.
7. Zwiebel JA, Cheson BD. Chronic lymphocytic leukemia: staging and prognostic factors. Semin Oncol. 1998; 25: 42-59.
8. Polliack A. Current therapeutic options for subgroups of chronic lymphocytic leukemia. Planning risk-adapted treatment according to recognized prognostic factors. Haematologica 2003; 88: 726-729.
9. Diehl LF, Karnell LH, Menck HR. The American College of Surgeons Comiss. Cancer and American Cancer Society. The National Cancer Data Base report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia. Cancer 1999; 86: 2684-2692.
10. Zengin N, Kars A, Sungurn A, Zengin NI, Hayran M, Tekuzman G, Kansu E, Ruacan S, Firat D. The significance of the bone marrow biopsy pattern in chronic lymphocytic leukemia: a prognostic dilemma. Am J Hematol. 1999; 62: 208-211.
11. Molica S. Prognostic value of biological variables in B-cell chronic lymphocytic leukemia. Can we improve upon clinical parameters. Haematologica 1997; 82: 705-709.
12. Hallek M, Langenmayen I, Nerl C, Knauf W, Dietzfelinger H, Adorf D, Ostwald M, Busch B, Kuhn-Halle I, Thiel E, Emmerich B. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, non-smoldering chronic lymphocytic leukemia. Blood 1999; 93: 1732-1737
13. 2-microglobulin level is more powerful than stage in predicting response and survival in chronic lymphocytic leukemia. Blood 1995; 86 (suppl 1) 606a.
14. Christiansen I, Gidlof C, Wallgren AC, Simonsson B, Totterman TH. Serum levels of soluble intercellular adhesion molecule 1 are increased in chronic B-lymphocytic leukemia and correlate with clinical stage and prognostic markers. Blood 1994; 84: 3010-3016.
15. Molica S, Levato D, Dell'Olio M, Cascavilla N., Matera R, Minervini M, Dattilo A, Carotenuto M, Musto P. Clinico-prognostic implications of increased levels of soluble CD54 in the serum of B-cell chronic lymphocytic leukemia patients: Results of multivariate survival analysis. Hematologica 1997; 82: 148-151.
16. Fayad I, Keating MJ, O'Brien S, Talpaz M, Kurzrock R. High serum interleukin-6 and serum interleukin-10 levels correlate with poor survival in chronic lymphocytic leukemia patients. J Clin Oncol. 1999; 18 (suppl 1) 24a.
17. Aguayo A, O'Brien S, Keating M, Manshouri T, Gidel C. Barlogie B, Beran M, Koller C, Kantarjian H, Albitar M. Clinical relevance of intracellular vascular endothelial factor levels in B-cell chronic lymphocytic leukemia. Blood 2000; 96: 768-770.
18. Molica S, Vitelli G, Levato D, Gandolfo GM, Liso V. Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia. Br J Haematol. 1999; 107: 605-610.
19. Góra-Tybor J, Błoński JZ, Robak T. Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia. Mediators Inflamm 2003; 12: 167-171.
20. Juliusson G, Oscier DG, Fitchett M, Ross FM, Stockdil G, Mackie MJ, Parker AC, Castoldi GI, Guneo A, Knuutila S, Elonen E, Gahrton G. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med. 1990; 323: 720-724.
21. Juliusson G, Merup M. Cytogenetics in chronic lymphocytic leukemia. Semin Oncol. 1998; 25: 19-26.
22. Dohner H, Stilgenbauer S, Dohner K, Bentz M, Lichter P. Chromosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis. J Mol Med. 1999; 77: 266-281.
23. Jamroziak K, Robak T. Cytogenetyka i biologia molekularna przewlekłej białaczki limfatycznej B-komórkowej. Acta Haematol. Pol. 2000; 31: 103-112.
24. Keating MJ. Montserrat E. Chronic lymphocytic leukemia: ase-based sesion Hematology 20001, Educational Program Book Orlando. December 7-11, 2001; 140-156.
25. Oscier DG, Thompsett A, Zbu D, Stevenson FK. Differential rates of somatic hypermutation in V(H) genes among subsets of chronic lymphocytic leukemia defined by chromosomal abnormalities. Blood 1997; 89: 4153-4160.
26. Naylor M, Capra D. Mutational status of Ig VH genes provides clinically valuable information in B-cell chronic lymphocytic leukemia. Blood 1999; 94: 1837-1839.
27. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848-1854.
28. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, Buchinder A, Budman D, Dittmar K, Kolitz J, Lichtman SM, Schulman P, Vinciguerra VP, Rai KR, Ferrarini M, Chiorazzi N. Ig V gene mutation status and CD38 expression as novel prognostic indication in chronic lymphocytic leukemia. Blood 1999; 94: 1840-1847.
29. Krober A, Seiler T, Benner A, Bullinger L, Bruckle E, Lichter P, Dohner H, Stilgenbauer S. V(H) mutation status, CD38 expression level, genomic aberrations and survival in chronic lymphocytic leukemia. Blood 2002; 200: 1410-1416.
30. Magnac C, Porcher R, Davi F, Nataf J, Paylle-Brogard B, Tang RP, Oppezzo P, Levy V, Dighero G, Ajchenbaum-Cymbalista F. Predictive value of serum tymidine kinase level for Ig-V mutational status in B-CLL. Leukemia 2003; 17: 133-137.
31. El Rouby S, Thomas A, Costin D, Rosenberg CR, Potemsil M, Silber R, Newcomb EW. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 1993; 82: 3452-3459.
32. Döhner H, Fischer K, Bentz M, Hansen K, Benner A, Cabo TG, Diehl D, Schleuk R, Coy J, Stilgenbauer S. i wsp. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995; 85: 1580-1589.
33. Osicer DG, Gardiner AC, Mould SJ, Glide S, Davis ZA, Ibborson RE, Corcoran MM, Chapman RM, Thomas W, Copplestone JA, Orchard JA, Hamblin TJ. Multivariate analysis of prognostic factors in CLL: clinical stage IgVH gene mutational status and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002; 100: 1177-1184.
34. Lin K, Sherrington PD, Dennis M, Matral Z, Cawley JC, Pettitt AR. Relationship between p53 dysfunction, CD38 expression and IgVH mutation in chronic lymphocytic leukemia. Blood 2002; 100: 1404-1409.
35. Deaglio S, Mallone R, Baj G, Arnulfo A, Surico N, Dianzani U, Mehta K, Malavasi F. CD38/CD31, a receptor/ligand system ruling achesion and signaling in human leukocytes. Chem Immunol. 2000; 77: 99-120.
36. Kumagai M, Coustan-Smith E, Murray DJ, Silvennoinen O'Murti KG, Evans WE, Malavasi K, Campana D. Ligation of CD38 suppress human B lymphopoiesis. J Exp Med. 1995; 181: 1101-1110.
37. Durig J, Nascha M, Schumucker U, Renzing-Kohler K, Holter T, Huttmann A, Duhrsen U. CD38 expression is an important prognostic marker in chronic lymphocytic leukemia. Leukemia 2002; 16: 30-35.
38. Ibrahim S, Keating M, Dook A, O'Brian S, Huh Y.O, Jilani I, Lerner S, Kantarjian H.M, Albitar M. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 2001; 98: 181-186.
39. Hamblin T, Orchard JA, Ibbotson RE, Davis Z, Thomas PW, Stevenson FK, Oscer DG. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002; 99: 1023-1029.
40. Del Poeta G, Maurillo L, Venditti A, Buccisano F, Epiceno A.M, Capelli G, Tamburini A, Sappo S, Battaglia A, Del Principle M.I, Del Moro B, Masi M, Amadori S. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood 2001; 98: 2633-2639.
41. O Morabito F, Mangida M, Oliva B, Stelitano C, Callea V, Deaglio S, Iacopino P, Briugiatelli M, Malavasi F. Peripherall blood CD38 expression predict survival in B-cell chronic lymphocytic leukemia. Leuk Res 2001; 25: 927-932.
42. D'Arena G, Musto P, Cascavilla N, Dell'Olio M, Di Renzo N, Perla G, Savino L, Carotemuto M. CD38 expression correlates with adverse biological features and predicts poor clinical outcome in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2001; 42: 109-114.
43. Heintel D, Schwarzinger I, Chizzali-Bonfadin C, Thalhammer R, Schwarzmeier J, Fritzer Szeheres M, Weltermann A, Simonitsch I, Lechner K, Jeger U. Association of CD38 antigen expression with other prognostic parameters in early stages of chronic lymphocytic leukemia. Leuk Lymphoma 2001; 42: 1315-1321.
44. Domingo-Domenech E, Domingo-Claros A, Gonzalez-Barca E, Beneitez D, Alonso E, Romagosa V, De Sanjos S, Petit J, Granena A, Fernandez de Sevilla A. CD38 expression in B chronic lymphocytic leukemia: association with clinical presentation and outcome in 155 patients. Haematologica 2002; 87: 1021-1027.
45. Morabito F, Mangiola M, Stelitano C, Deaglio S, Callea V, Malavasi F. Peripheral blood CD38 expression predics time to progression in B-cell chronic lymphocytic leukemia after first-line therapy with high - dose chlorambucil. Haematologica 2002; 87: 217-218.
46. Chan AC, Iwashima M, Turck CW, Weiss A. ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR zeta chain. Cell 1992; 71: 649-662.
47. Latour S, Veillette A. Proximai protein tyrosine kinases in immunoreceptor signaling. Curr Opin. Immunol. 2001; 13: 299-306.
48. Klein U, Tu Y, Stolovitzky GA, Mattioei M, Cattoretti G, Husson H, Freedman A, Inghirami G, Cro L, Baldini L, Neri A, Califano A, Dalla-Favera R. Gene expression profiling of B-cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med. 2001; 194: 1625-1638.
49. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, Yang L, Pickeral OK, Rassenti LZ, Powell J, Botstein D, Byrd JC, Grever MR, Cheson BD, Chiorazzi N, Wilston WH, Kipps TJ, Brown PO, Stawdt LM. Relation of gene expression phenotype immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001; 194: 4087-4093.
50. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, Marce S, Lopes-Guillermo A, Campo E, Montserrat E. ZAP-70 expression as a surrogate for immunoglobulin - variable - region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003; 348: 1764-1775.
51. Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE, Zhao H, Ibbotson RE, Orchard JA, Davis Z, Steiter-Stevenson M, Raffeld M, Arthur DC, Marti GE, Wilson WH, Hamblin TJ, Oscier DG, Staudt LM. ZAP-70 expression identities a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003; 101: 4944-4951.
52. Orchard JA, Ibbotson RE, Davis Z, Wiestner A, Rosenwald A, Thomas PW, Hamblin TJ, Standt LM, Oscier DG. ZAP-70 expression by flow cytometry: a new prognostic marker in CLL. Lancet 2003; (w druku).
53. Dighiero G, Binet JL. When and how to treat chronic lymphocytic leukemia. N Engl J Med. 2000; 343: 1799-1801.
54. Rai K.R, Chiorazzi N. Determining the clinical course and outcome in chronic lymphocytic leukemia. N Engl J Med. 2003; 348: 1797-1799.
55. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR. National Cancer Institute sponsored Working Group guidelines for chronic lymphocytic leukemia: revised quidelines for diagnosis and treatment. Blood 1996; 87: 4990-4997.